Zuellig Pharma Signs a 10-Year Commercialisation Partnership with Institut Allergosan
Zuellig Pharma signs a 10-year commercialisation partnership with Institut AllergoSan to bring leading probiotic brand OMNi-BiOTiC to key markets in Asia
Overview
Zuellig Pharma, a leading healthcare solutions company in Asia, announced that it has signed a 10-year commercialisation partnership with Austria-based Institut AllergoSan, a research and development company that specialises in products made from natural substances such as probiotic bacteria, plant extracts and minerals.
Partnership for OMNi-BiOTiC
Anita Frauwallner, founder and CEO of Institut AllergoSan (left) and John Graham, Group CEO, Zuellig Pharma (right) at the partnership signing ceremony to bring OMNi-BiOTiC to key markets in Asia.
Under the Partnership
Under this partnership, Zuellig Pharma will provide a wide spectrum of commercialisation support, including product registration, sales and marketing, and warehousing and distribution services to bring OMNi-BiOTiC, one of Institut AllergoSan's leading probiotic brands, to key markets in Asia.
Words from CEO: Zuellig Pharma
"Our consumer healthcare segment will be one of the key growth drivers in our business over the coming years and this partnership represents a significant step forward in our commitment to delivering innovative and accessible healthcare solutions to patients in Asia. With a fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered through our commercialisation division, ZP Therapeutics, will help our partners expand their footprint to meet greater consumer demand for gut health products in this region.”
“Together with Institut AllergoSan, we will leverage our combined expertise to enhance the well-being of consumers and drive forward our mission of making healthcare more accessible,"" said John Graham, Group CEO, Zuellig Pharma.
Words from CEO: Institut AllergoSan
"We are dedicated to supporting consumers' pursuit of a healthier, more vital self and offer medically relevant probiotic supplements that target specific health needs and deliver clinically backed results. OMNi-BiOTiC is the top selling probiotic brand in all German-speaking markets in Europe such as Austria, Germany and Switzerland and we look forward to working closely with Zuellig Pharma to bring these innovative products to everybody in Asia who wants to promote an active, healthy life," adds Anita Frauwallner, founder and CEO of Institut AllergoSan.
Future launch- Zuellig Pharma plans to launch OMNi-BiOTiC in Indonesia, the Philippines and Taiwan in 2025, followed by other key markets thereafter.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve.
The company provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region.
About Institut AllergoSan
Institut AllergoSan, based in Graz, Austria, was founded in 1991 by a group of integrative doctors and pharmacists together with Anita Frauwallner, who is now the managing director.
Since then, the company has been focused on the scientific research and development of products made from natural substances such as probiotic bacteria, dietary fibres, micronutrients, and plant extracts.